BioSpace News Archive

Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will present at Morgan Stanley’s Annual Global Healthcare Conference in New York, NY on Monday, September 9, 2019 at 11:05am Eastern time.

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biotechnology company developing potential first-in-class product candidates for cancers with critical unmet medical needs, today announced the appointment of Frank Hsu, M.D., as Chief Medical Officer, and Rajesh Krishnan, Ph.D., as Senior Vice President, Chemistry, Manufacturing and Controls (CMC) and Manufacturing.

Triple-S Management Corporation (NYSE: GTS) today announced that its President and Chief Executive Officer Roberto García-Rodríguez, and its EVP and Chief Financial Officer Juan José Román-Jiménez will participate in a fireside chat at the 2019 Wells Fargo Healthcare Conference on Wednesday, September 4, 2019 at the Westin Copley Place in Boston, Massachusetts.

Veracyte, Inc. (Nasdaq: VCYT) today announced that Bonnie H. Anderson, chairman and chief executive officer, will present at the following upcoming investor conferences:

Oticon Xceed and Oticon Xceed Play, plus the new Oticon CROS solution for single-sided deafness extend the open sound experience to even more adults and children with hearing loss

Eagle Pharmaceuticals, Inc. announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the Morgan Stanley 17th Annual Global Healthcare Conference as follows:

Quest Diagnostics Incorporated, the world’s leading provider of diagnostic information services, announced that it is scheduled to speak at the Morgan Stanley Global Healthcare Conference in New York.

Family Research Council applauded the Department of Health and Human Services Office for Civil Rights for issuing a Notice of Violation against the University of Vermont Medical Center for unlawfully forcing a nurse to assist in an abortion.

EdiGENE Corporation announced that the company has changed its name to Modalis Therapeutics Corporation.

Esco Ventures is pleased to announce the launch of Carmine Therapeutics and execution of an exclusive license agreement for the technology developed in the laboratories of Professors Minh Le and Jiahai Shi at the City University of Hong Kong.